Shots:
- Health Canada has approved Libtayo (cemiplimab) for the adj. treatment of adults with CSCC who are at high risk for recurrence after surgery & radiation
- Approval was based on the P-III (C-POST) trial assessing adj. Libtayo (n=209) vs PBO (n=206) to treat high-risk CSCC pts (N=415)
- Trial showed a 68% reduction in disease recurrence & death risk, with a median follow-up of 24mos. (24 vs 65 events); data was published in The NEJM
Ref: CA newswire | Image: Regeneron | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
